Therapeutic Strategies for Long-QT Syndrome
- 1 October 2008
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Arrhythmia and Electrophysiology
- Vol. 1 (4), 290-297
- https://doi.org/10.1161/circep.108.795617
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Syntrophin mutation associated with long QT syndrome through activation of the nNOS–SCN5A macromolecular complexProceedings of the National Academy of Sciences of the United States of America, 2008
- Mutation of an A-kinase-anchoring protein causes long-QT syndromeProceedings of the National Academy of Sciences of the United States of America, 2007
- Identifying genetic risk factors for serious adverse drug reactions: current progress and challengesNature Reviews Drug Discovery, 2007
- SCN4B -Encoded Sodium Channel β4 Subunit in Congenital Long-QT SyndromeCirculation, 2007
- Nonsense Mutations in hERG Cause a Decrease in Mutant mRNA Transcripts by Nonsense-Mediated mRNA Decay in Human Long-QT SyndromeCirculation, 2007
- Intragenic Suppression of Trafficking-Defective KCNH2 Channels Associated with Long QT SyndromeMolecular Pharmacology, 2005
- A novel SCN5A mutation manifests as a malignant form of long QT syndrome with perinatal onset of tachycardia/bradycardiaCardiovascular Research, 2004
- New KCNQ1 mutations leading to haploinsufficiency in a general population1Defective trafficking of a KvLQT1 mutantCardiovascular Research, 2004
- Thapsigargin Selectively Rescues the Trafficking Defective LQT2 Channels G601S and F805COnline Journal of Public Health Informatics, 2003
- Pharmacological targeting of long QT mutant sodium channels.JCI Insight, 1997